Iterion Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Iterion Therapeutics's estimated annual revenue is currently $1.2M per year.
- Iterion Therapeutics's estimated revenue per employee is $77,500
- Iterion Therapeutics's total funding is $21.4M.
Employee Data
- Iterion Therapeutics has 16 Employees.
- Iterion Therapeutics grew their employee count by 7% last year.
Iterion Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Sr. Director, Research and Non-clinical Development | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Director Clinical Operations | Reveal Email/Phone |
Iterion Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.5M | 16 | 45% | N/A | N/A |
#2 | $13.8M | 89 | -7% | N/A | N/A |
#3 | $18.6M | 120 | 3% | $1.8M | N/A |
#4 | $0.9M | 6 | -40% | N/A | N/A |
#5 | $4.2M | 27 | 0% | N/A | N/A |
#6 | $3.4M | 22 | 47% | N/A | N/A |
#7 | $9.6M | 62 | 29% | N/A | N/A |
#8 | $0.9M | 6 | 20% | N/A | N/A |
#9 | $1.7M | 11 | 10% | N/A | N/A |
#10 | $15.2M | 98 | -8% | N/A | N/A |
What Is Iterion Therapeutics?
Iterion Pharmaceuticals is a venture-backed, clinical stage biotechnology company developing novel targeted cancer therapeutics. The company’s lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/ -catenin signaling pathway, which is implicated in cell proliferation, differentiation, migration, apoptosis, immune evasion and stem cell renewal. Tegavivint has demonstrated pre-clinical in vivo efficacy in several cancer models, including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and multiple solid tumor types. The Company is enrolling a Phase I clinical study to evaluate safety and efficacy of Tegavivint in patients with desmoid tumors.
keywords:N/A
$21.4M
Total Funding
16
Number of Employees
$1.2M
Revenue (est)
7%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Iterion Therapeutics News
HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel...
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 16 | N/A | N/A |
#2 | $1.4M | 16 | N/A | N/A |
#3 | $3.1M | 16 | -33% | N/A |
#4 | $2.4M | 16 | 0% | N/A |
#5 | $1.2M | 16 | 23% | $10M |